Tonix Pharmaceuticals Holding Corp. (TNXP)

TNXP stock forecast: buy or sell

TNXP stock outlook

  • Tonix Pharmaceuticals closed on Friday at $1.16 after sinking a -3.33%.
  • Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing drugs and biologics to treat various diseases.
No ad for you

The thoughts given in this post are personal and should not be followed as recommendations for you to buy or sell shares. The author of this article does not have any knowledge of the particular scenarios of the reader, his or her financial statements or his or her own best interests at any given time. All users should speak with their financial advisor before buying or selling any securities Opinions are published for informational purposes only

TNXP stock chart overview

Should I buy Tonix Pharmaceuticals stock?

All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best

Is TNXP stock a buy?

Currently, Tonix Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy now. This doesn't mean TNXP will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems

No ad for you

Should I sell Tonix Pharmaceuticals stock?

When you are a novel trader and you own stock shares with some profit, it's really hard to decide the best moment to sell and get your benefits. In the same way as when we have to buy shares, choosing when is the best time to sell is not a random decision, and we must adhere our own trading strategy. We like very simple setups to guide us on when is a good time to sell a stock. Be aware that these setups are not intended for selling short Tonix Pharmaceuticals stock

A guiding principle is that you should never hold a trade that produces losses greater than those expected at the time of purchase. The timing to sell shares should always be determined by the stop-loss (automatic or manual)

Is it time to sell Tonix Pharmaceuticals stock?

In the current situation of Tonix Pharmaceuticals there is not any eligible sell setup, so Tonix Pharmaceuticals stock holders with operations in profit can keep their positions

No ad for you

Analysts' recommendations to buy or sell Tonix Pharmaceuticals stock

Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal

We don't have any rating posted in the previous month for Tonix Pharmaceuticals

No ad for you

Technical analysis

SMAs overview

A favorite tool of many technical analysts are the moving averages, that easily show trend direction. A moving average is the average price of a stock over a set period of time. Moving averages are usually calculated on different periods depending on the trading timeframe 21, 50, 100 and 200 days are the most usual moving averages

Supports and resistances

Traders use support and resistance levels to identify price points on a chart that may work as barriers, containing the price of a stock to move up or down. A support level is a level where the price tends to stop as it falls. This means that the price is more likely to "rebound" this level rather than break through it. Nevertheless, if the price breaks down the support, it will probably continue descending until approaching another support level. On the contrary, resistance levels are where the price may find a curb as it moves up. Likewise, the price is more likely to "bounce off" at this level, and if it finally ruptures this level, it will rise easily until it approaches the next resistance

The current resistances are:

  • R1: $1.30 (12.07% above)
  • R2: $1.72 (48.28% above)
  • R3: $1.98 (70.69% above)
  • The current support levels are:

  • S1: $1.01 (-12.93% below)
  • S2: $0.86 (-25.86% below)
  • S3: $0.84 (-27.59% below)
  • Bollinger bands

    This is an indicator that was created in the 1980s by John Bollinger. Fundamentally, the Bollinger Bands are lines that flow around a centralmoving average, ranging the distance from the bottom to the top depending on market volatility. They are usually drawn by an offset of two standard deviations, above and below, from a moving average line. Bollinger himself recommends the moving average period to be 20

    Relative strength index

    The RSI (Relative Strength Index) is an oscillator-type indicator that track price action to spot when the price of a share or financial asset is overbought or oversold. Like other oscillation indicators, the RSI fluctuates in a range from 0% to 100%. The relative strength indicator is one of the best known and most widely used indicators, and it was invented by J. Welles Wilder in 1978

    The RSI dropped below the overbought level of 70 on July 24 after just crossing to the overbough zone for just one day (weak signal). The RSI reading on Friday was 53.82. Tonix Pharmaceuticals shares tanked a 23.18% since then

    No ad for you

    Earnings and financials

    Tonix Pharmaceuticals Holding Corp. (TNXP) posted EPS for the fiscal Q1 that grossly failed to match Wall St. expectations. Quarterly EPS was $-2.86 per share vs. $-1.49. This Q1 report represents an earnings surprise of -91.95%. On the contrary, the company said turnover for this quarter was $0.00 aligned with analysts' forecasts.

    Compared to the same quarter one year ago, EPS was $-61.00, so posted EPS means a improvement of 95.31%. Looking at turnover, figures barely changed compared to $0.00 year over year.

    TNXP will host the Q2 earnings call on Monday next week. Wall Street analysts predict an Earnings per Share of $-0.22, that is a 92.31% higher than previous quarter. Earnings reporting day has a more than usual risk for stock investors as the results provided can gap up or down the stock price with exceptionally low liquidity and not honouring your buy/stop-loss orders. It's always good to review company's website to confirm time and details on the earnings call and the earnings report.

    No ad for you